Successful rechallenge of bevacizumab after grade 4 bevacizumab induced hypertension in a case of carcinoma ovary, is rechallenging an option? - A Rare case report

📝 Copyright, Licensing and Permissions: © Copyright Author(s). This article is published under the 🌐 Creative Commons Attribution 4.0 International License (CC BY 4.0) , which permits unrestricted use, distribution, adaptation, and reproduction in any medium, provided the original author(s) and source are properly credited, a link to the license is provided, and any changes made are indicated.

⚠️ Disclaimer: The statements, opinions, interpretations, and data presented in this publication are solely those of the individual author(s). GSC Biological and Pharmaceutical Sciences (GSCBPS), the editors, reviewers, editorial board, and publisher disclaim responsibility for any errors, omissions, or consequences arising from the use of the information contained in this article.